Secretion and antifibrinolytic function of thrombin-activatable fibrinolysis inhibitor from human platelets

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 11, 2010, Pages 2523-2529

  Schadinger, S L ^a   Lin, J H H ^a   Garand, M ^b   Boffa, M B ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF WINDSOR   (Canada)

Author keywords

granules; Carboxypeptidases; Fibrinolysis; Platelets; TAFI

Indexed keywords

THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; ENZYME MECHANISM; ENZYME RELEASE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; WESTERN BLOTTING;

ANTIFIBRINOLYTIC AGENTS; BINDING SITES; BLOOD COAGULATION; BLOOD PLATELETS; CARBOXYPEPTIDASE U; FIBRINOLYSIS; HUMANS; LYSINE; PROTEIN STRUCTURE, TERTIARY; PROTHROMBIN; THROMBOSIS; VON WILLEBRAND FACTOR;

EID: 78149277497     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.04024.x     Document Type: Article

References (26)

1. Hoffman M, Monroe DM. A cell-based model of hemostasis. Thromb Haemost 2001; 85: 958-65.
2. Wohner N. Role of cellular elements in thrombus formation and dissolution. Cardiovasc Hematol Agents Med Chem 2008; 6: 224-8.
3. Weisel JW. Structure of fibrin: impact on clot stability. J Thromb Haemost 2007; 5: 116-24.
4. Kolev K, Longstaff C, Machovich R. Fibrinolysis at the fluid-solid interface of thrombi. Curr Med Chem Cardiovasc Hematol Agents 2005; 3: 341-55.
5. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006; 26: 2445-53.
6. Boffa MB, Koschinsky ML. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin Biochem 2007; 40: 431-42.
7. Eaton D, Malloy B, Tsai S, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
8. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
9. Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273: 2127-35.
10. Hendriks D, Wang W, Scharpé S, Lommaert M, Van Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034: 86-92.
11. Shinohara T, Sakurada C, Suzuki T, Takeuchi O, Campbell W, Ikeda S, Okada N, Okada H. Pro-carboxypeptidase R cleaves bradykinin following activation. Int Arch Allergy Immunol 1994; 103: 400-4.
12. Tan AK, Eaton DL. Activation and characterization of procarboxypeptidase B from human plasma. Biochemistry 1995; 34: 5811-16.
13. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
14. Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JCM, Bouma BN. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood 2003; 101: 4844-6.
15. Gils A, Alessi MC, Brouwers E, Peeters M, Marx P, Leurs J, Bouma B, Hendriks D, Juhan-Vague I, Declerk PJ. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-7.
16. Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000; 275: 12868-78.
17. Mustard JF, Kinlough-Rathbone RL, Packham MA. Isolation of human platelets from plasma by centrifugation and washing. Methods Enzymol 1989; 169: 3-11.
18. Kim PY, Foley J, Hsu G, Kim PY, Nesheim ME. An assay for measuring functional activated thrombin-activatable fibrinolysis inhibitor in plasma. Anal Biochem 2008; 372: 32-40.
19. Mutch NJ, Moore NR, Wang E, Booth NA. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003; 1: 2000-7.
20. 2-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots. J Thromb Haemost 2007; 5: 812-17.
21. Robbie LA, Young SP, Bennett B, Booth NA. Thrombi formed in a Chandler loop mimic human arterial thrombi in structure and PAI-1 content and distribution. Thromb Haemost 1997; 77: 510-15.
22. Buelens K, Hillmayer K, Compernolle G, Declerck PJ, Gils A. Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor. Circ Res 1998; 102: 295-301.
23. Skaer RJ, Emmines JP, Skaer HB. The fine structure of cell contacts in platelet aggregation. J Ultrastruct Res 1979; 69: 28-42.
24. Coppinger JA, Cagney G, Toomey S, Kislinger T, Belton O, McRedmond JP, Cahill DJ, Emili A, Fitzgerald DJ, Maguire PB. Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions. Blood 2004; 103: 2096-104.
25. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 1021-30.
26. Brass LF, Stalker TJ, Zhu L, Woulfe DS. Signal transduction during platelet plug formation. In: Michelson AD, ed. Platelets, 2nd edn. Burlington, MA: Academic Press, 2007: 2: 319-346.